<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Omar M. Alsaffar</style></author><author><style face="normal" font="default" size="100%">Maha T. Al-Saffar</style></author><author><style face="normal" font="default" size="100%">Abdulsattar S. Mahmood</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lisinopril-Induced CD34 Bone Healing Marker</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Bone healing</style></keyword><keyword><style  face="normal" font="default" size="100%">Bone injury</style></keyword><keyword><style  face="normal" font="default" size="100%">CD34.</style></keyword><keyword><style  face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style  face="normal" font="default" size="100%">Lisinopril</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">208-211</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor that is commonly used to treat high blood pressure and heart failure. While it is generally well-tolerated, some studies have suggested that it may affect bone healing, suggesting that lisinopril treatment was associated with an increase in the CD34 bone healing marker in patients with tibial fractures. CD34 is a protein that is involved in the formation of new blood vessels and has been shown to play a role in bone healing. &lt;strong&gt;Methods: &lt;/strong&gt;The study used 24 rabbits with artificially induced tibial bone fracture divided into 4 groups (6 rabbits each), the control group treated with distilled water and 3 groups treated with lisinopril. Each group were sacrificed for immunohistochemical study on 3 timepoints at day 7, 14, and 21. &lt;strong&gt;Results: &lt;/strong&gt;Indicated that the lisinopril group had significantly higher levels of CD34 than the control group. &lt;strong&gt;Conclusion:&lt;/strong&gt; While the results of this study suggest that lisinopril may have a positive effect on bone healing, more research is needed to confirm these findings and to determine the mechanisms by which lisinopril may affect bone healing. It is also important to note that lisinopril may have other potential side effects, and patients should discuss any concerns with their healthcare provider&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">208</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Omar M. Alsaffar*, Maha T. Al- Saffar, Abdulsattar S. Mahmood&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;College of Dentistry, University of Mosul, Mosul, IRAQ.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">S Swarna Meenakshi</style></author><author><style face="normal" font="default" size="100%">Sheeja S Varghese</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Role of Recombinant Parathormone derivative in Bone healing. Making the Unfavorable, Favorable - A Systematic Review</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Bone healing</style></keyword><keyword><style  face="normal" font="default" size="100%">Fracture</style></keyword><keyword><style  face="normal" font="default" size="100%">Parathormone</style></keyword><keyword><style  face="normal" font="default" size="100%">Recombinant derivative</style></keyword><keyword><style  face="normal" font="default" size="100%">Teriparatide</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">November 2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">1753-1768</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Teriparatide is a recombinant parathormone derivative encompassing the first 1-34 amino acids off PTH, which is said to contain potent anabolic capability. It is said to induce osteoblastogenesis thereby placing an essential role in bone healing. The aim of this systematic review is to evaluate the best available evidence from randomized controlled trials analyzing the effectiveness of teriparatide on bone regeneration and healing in osteoporotic patients and patients with fractures. &lt;strong&gt;Aim:&lt;/strong&gt; This systematic review aims to assess whether Teriparatide enhances bone regeneration and healing in terms of improving clinical, radiographic, histologic parameters and Biomarkers of Bone formation and resorption. &lt;strong&gt;Materials and Methodology:&lt;/strong&gt; A comprehensive search was done in databases such as ‘PubMed’, ‘Google Scholar and ‘Cochrane’ databases based on pre-determined eligibility criteria. Randomized control trials assessing the effectiveness of Teriparatide in Bone healing in fractures as well as osteoporosis were selected after thorough screening.&lt;strong&gt; Results: &lt;/strong&gt;The selected 13 studies compared teriparatide to either placebo or another anti-resorptive drug. Out of the 13, 8 studies were done to evaluate the improvement and healing of bone in Osteoporotic patients whereas 5 studies were done on improvement in fracture healing. The studies evaluated outcome parameters such as Clinical and Radiological improvement, Biomarkers of Bone resorption and formation and Safety.6 studies assessed clinical parameters, 12 studies assessed radiological parameters, 7 studies assessed biomarkers, 11 studies assessed safety parameters by means of occurrence of any adverse effects. All the 8 studies done on osteoporotic patients showed a good improvement. Of the 5 studies on fracture healing, only 2 studies showed beneficial effects while the other 3 did not show any benefits. &lt;strong&gt;Conclusion:&lt;/strong&gt; Teriparatide could have beneficial effects in bone healing in osteoporotic patients and is well tolerated. However, the results are inconclusive whether they have beneficial effects in treating fractures. More Homogenous Randomized control trials are required to ascertain whether teriparatide could improve bone healing.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Review Article</style></work-type><section><style face="normal" font="default" size="100%">1753</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;S Swarna Meenakshi&lt;sup&gt;1,&lt;/sup&gt;*, Sheeja S Varghese&lt;sup&gt;2&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Post Graduate student, Department of Periodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University,Chennai, INDIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Professor, Department of Periodontics, Dean of Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, INDIA.&lt;/p&gt;
</style></auth-address></record></records></xml>